Cosentyx
Novartis reveals strong long-term data Cosentyx in psoriasis of the hands and feet
December 1, 2017Medical Communications, Research and Development Cosentyx, Novartis, palmoplantar psoriasis, pharma, psoriasis
Novartis has released new data for Consentyx (secukinumab) which it claims make the IL-17A inhibitor “the first biologic to show …
Top Ten most popular articles on Pharmafile.com this week
September 15, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cosentyx, Eli Lilly, Martin Skreli, Teva, pharma, top ten
This week has been a particularly eventful one for the industry: among our top stories, Martin Shkreli finally heads to …
Novartis’ Cosentyx proves long-term efficacy in psoriasis skin clearance
September 13, 2017Research and Development Cosentyx, Novartis, pharma, pharmaceutical, psoriasis
At the European Academy of Dermatology and Venereology Congress in Geneva, Switzerland, Novartis unveiled new Phase 3 data for Cosentyx …
Novartis’ Cosentyx shines in ankylosing spondylitis and psoriatic arthritis
June 15, 2017Research and Development Cosentyx, Novartis
Novartis has released new data on the efficacy of its drug Cosentyx (secukinumab) in the treatment of life-long inflammatory diseases …
Novartis’ psoriasis drug allows some patients to go into remission
March 21, 2017Research and Development Cosentyx, Novartis, psoriasis
Novartis released data on patient’s reaction to Cosentyx for the treatment of psoriasis, finding that as many as 21% of …
Novartis reveals positive three-year efficacy data for psoriatic arthritis drug
November 15, 2016Manufacturing and Production, Research and Development Cosentyx, Novartis, psoriatic arthritis
Novartis has claimed that its Cosentyx (secukinumab) treatment is now the first approved fully human interleukin-17A (IL-17A) inhibitor to demonstrate …
Novartis reveals impressive four year data upon Cosentyx
October 3, 2016Sales and Marketing Cosentyx, Novartis, psoriasis
Novartis announced on October 1 that Cosentyx (secukinumab) had delivered a high percentage and long-lasting skin clearance in patients with …
NICE recommends Cosentyx in ankylosing spondylitis
August 4, 2016Research and Development, Sales and Marketing Cosentyx, NICE, Novartis, ankylosing spondylitis
Novartis has announced that the National Institute for Health and Care Excellence (NICE) has recommended Cosentyx (secukinumab) to treat adults …
Novartis to compare Cosentyx with Humira in new clinical trials
June 8, 2016Research and Development Cosentyx, Humira, Novartis, comparison, eular 2016
Novartis has announced that it plans to directly compare Cosentyx (secukinumab) versus Humira (adalimumab) in patients with ankylosing spondylitis and …
Novartis says its psoriasis drug bests Janssen’s in comparison study
March 7, 2016Research and Development, Sales and Marketing Cosentyx, Novartis, Stelara
Novartis has announced new data from a study comparing its drug Cosentyx to Janssen’s Stelara, which it says demonstrates Cosentyx’s …
Two new US approvals for Novartis’ Cosentyx
January 18, 2016Research and Development, Sales and Marketing Cosentyx, Novartis
Novartis has won FDA approval for Cosentyx (secukinumab) for the treatment of two new indications – adults with active ankylosing …
Novartis’ Cosentyx shows benefits in Phase III AS trials
January 4, 2016Research and Development, Sales and Marketing Cosentyx, Novartis, Secukinumab, ankylosing spondylitis
Novartis says results from two Phase III studies for Cosentyx in ankylosing spondylitis (AS) showing significant clinical improvements versus placebo.Results …
Novartis’ Cosentyx gets European approval for two conditions
October 23, 2015Medical Communications, Sales and Marketing Cosentyx, European Medicines Agency, Novartis, psoriatic arthritis
The scientific committee of the European Medicines Agency (EMA) has recommended the approval of Novartis’ Cosentyx (secukinumab) for treatment of ankylosing …
Novartis psoriasis drug shows three-year efficacy
October 12, 2015Cosentyx, EADV, Novartis, Secukinumab, psoriasis
Novartis has announced new trial data confirming the efficacy of Cosentyx in patients with moderate-to-severe plaque psoriasis. The results of …
Novartis spends $200m on pain firm Spinifex
June 29, 2015Sales and Marketing Cosentyx, EMA401, Novartis, Secukinumab, spinifex
Novartis is spending $200 million to increase its presence in pain management through the purchase of US-Australian biotech Spinifex Pharmaceuticals. …
Latest content
Five Facts about cardiovascular disease
